Antinörodejeneratif 5-sübstitüe 2,4-tiyazolidindion Türevlerinin Kuantum Kimyasal İncelemesi

Öz

Antihiperglisemik, antikanser, antioksidan ve antinörodejeneratif gibi farklı farmakolojik özellikler gösteren 5-sübstitüe 2,4-tiazolidindion türevleri, elektronik ve geometrik özelliklerini aydınlatmak amacıyla kuantum kimyasal olarak incelenmiştir. Bileşiklerin üç boyutlu yapıları B3LYP fonksiyoneli ile üç farklı temel set (6-31G, 6-31G(d) ve 6-31G(d,p)) kullanılarak optimize edilmiştir. Mulliken yükleri, dipol momentleri, HOMO ve LUMO enerjileri de aynı yöntem ile hesaplanmıştır. Hesaplanan geometrik parametreler, farklı temel setler için deneysel sonuçlar ile karşılaştırılmıştır. Elde edilen kuantum kimyasal hesaplama sonuçlarına göre, teorik bağ uzunlukları ve açıları deneysel verilerle uyum içerisindedir. HOMO ve LUMO enerji değerleri farkı analiz edildiğinde, ele alınan 5-sübstitüe 2,4-tiazolidindion türevleri içerisinde 24 numaralı bileşiğin en reaktif bileşik olduğu belirlenmiştir.

Anahtar Kelimeler

• Alzheirmer
• antinörodejeneratif
• yoğunluk
• fonksiyonel teorisi
• tiyazolidindion

Quantum Chemical Investigation of a Series of 5-substituted 2,4-thiazolidinedione Derivatives as Antineurodegenarative Agents

Öz

A series of 5-substituted 2,4-thiazolidinedione derivatives which exhibit different pharmacological properties such as anti-hyperglycemic, anticancer, antioxidant and anti-neurodegenerative has been quantum chemically investigated to clarify elucidated electronic and geometrical features. B3LYP functional with three different basis sets including 6-31G, 6-31G(d) and 6-31G(d,p) was made use of to optimize the three-dimensional structures of the compounds. Mulliken charges, dipole moments, energies of the HOMO and LUMO were also calculated with the same methods. The calculated geometrical parameters were compared with the experimental data to analyze the results of the different basis set. According to the quantum chemical calculation results obtained, the theoretical bond lengths and angles show good compatibility with the experimental data. Based on the HOMO and LUMO energy gap analysis, compound 24 was found to be the most reactive one in the 5-substituted 2,4-thiazolidinedione derivatives under study.

Anahtar Kelimeler

• Alzheimer’s disease
• antineurodegenarative
• density functional theory
• thiazolidinedione

Kaynakça

1. Alzheimer’s Association (2019) Alzheimer’s Disase Facts and Figures. Alzhimers Dement, 15(3):321-87.
2. Bahare, R. S., Ganguly, S., Choowongkomon, K., & Seetaha, S. (2015). Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones. DARU, Journal of Pharmaceutical Sciences, 23(1). https://doi.org/10.1186/s40199-014-0086-1
3. Balsinha, C., Gonçalves-Pereira, M., Iliffe, S., Freitas, J. A., & Grave, J. (2019). World Alzheimer Report 2019. Alzheimer’s Disease International. https://doi.org/10.1007/978-3-030-10814-4_23
4. Becke, A. D. (1993). A new mixing of Hartree-Fock and local density-functional theories. The Journal of Chemical Physics, 98(2), 1372–1377. https://doi.org/10.1063/1.464304
5. Becke, A. D. (1993). Density-functional thermochemistry. III. The role of exact exchange. The Journal of Chemical Physics, 98(7), 5648–5652. https://doi.org/10.1063/1.464913
6. Cummings, J. L., Morstorf, T., & Zhong, K. (2014). Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimer’s Research and Therapy, 6(4), 37. https://doi.org/10.1186/alzrt269
7. Day, C. (1999). Thiazolidinediones: A new class of antidiabetic drugs. Diabetic Medicine, 16(3), 179–192. https://doi.org/10.1046/j.1464-5491.1999.00023.x
8. Desai, A., & Grossberg, G. (2001). Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders. Expert Opinion on Pharmacotherapy, 2(4), 653–666. https://doi.org/10.1517/14656566.2.4.653

9. Form, G. R., Raper, E. S., & Downie, T. C. (1975). The crystal and molecular structure of thiazolidine-2,4-dione. Acta Crystallographica Section B Structural Crystallography and Crystal Chemistry, 31(9), 2181–2184. https://doi.org/10.1107/s0567740875007212
10. Gandini, A., Bartolini, M., Tedesco, D., Martinez-Gonzalez, L., Roca, C., Campillo, N. E., … Bolognesi, M. L. (2018). Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. Journal of Medicinal Chemistry, 61(17), 7640–7656. https://doi.org/10.1021/acs.jmedchem.8b00610
11. González, J. F., Alcántara, A. R., Doadrio, A. L., & Sánchez-Montero, J. M. (2019). Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches. Expert Opinion on Drug Discovery, 14:9, 879–891. https://doi.org/10.1080/17460441.2019.1623201
12. Holmes, C., Wilkinson, D., Dean, C., Vethanayagam, S., Olivieri, S., Langley, A., … Damms, J. (2004). The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology, 63(2), 214 LP – 219. https://doi.org/10.1212/01.WNL.0000129990.32253.7B
13. Hughes, R. E., Nikolic, K., & Ramsay, R. R. (2016). One for all? Hitting multiple Alzheimer’s disease targets with one drug. Frontiers in Neuroscience, 10(APR), 1–10. https://doi.org/10.3389/fnins.2016.00177
14. Hyde, C., Peters, J., Bond, M., Rogers, G., Hoyle, M., Anderson, R., … Moxham, T. (2013). Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: Systematic review and economic model. Age and Ageing, 42(1), 14–20. https://doi.org/10.1093/ageing/afs165
15. Kumar, A., Tiwari, A., & Sharma, A. (2018). Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design. Current Neuropharmacology, 16(6), 726–739. https://doi.org/10.2174/1570159x16666180315141643
16. Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X. (2019). Drug development for Alzheimer’s disease: review. Journal of Drug Targeting, 27(2), 164–173. https://doi.org/10.1080/1061186X.2018.1474361
17. Lee, C., Yang, W., & Parr, R. G. (1988). Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Physical Review B, 37(2), 785–789. https://doi.org/10.1103/PhysRevB.37.785
18. Liu, Y., Nguyen, M., Robert, A., & Meunier, B. (2019). Metal Ions in Alzheimer’s Disease: A Key Role or Not? Accounts of Chemical Research, 52(7), 2026–2035. https://doi.org/10.1021/acs.accounts.9b00248
19. Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015). Alzheimer’s disease. Nature Reviews Disease Primers, 1, 1–18. https://doi.org/10.1038/nrdp.2015.56
20. M. J. Frisch, G., Trucks, W., Schlegel, H. B. ., Scuseria, G. E. ., Robb, M. A. ., Cheeseman, J. R., … Fox, D. J. (2009). Gaussian 09, Revision E. 01; Gaussian. Gaussian, Inc.: Wallingford, CT. https://doi.org/111
21. Mulliken, R. S. (1955). Electronic population analysis on LCAO-MO molecular wave functions. I. The Journal of Chemical Physics, 23(10), 1833–1840. https://doi.org/10.1063/1.1740588
22. Mulliken, R. S. (1955). Electronic population analysis on LCAO-MO molecular wave functions. II. Overlap populations, bond orders, and covalent bond energies. The Journal of Chemical Physics, 23(10), 1841–1846. https://doi.org/10.1063/1.1740589
23. Mulliken, R. S. (1955). Electronic population analysis on LCAO-MO molecular wave functions. III. effects of hybridization on overlap and gross AO populations. The Journal of Chemical Physics, 23(12), 2338–2342. https://doi.org/10.1063/1.1741876
24. Naim, M. J., Alam, M. J., Ahmad, S., Nawaz, F., Shrivastava, N., Sahu, M., & Alam, O. (2017). Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship. European Journal of Medicinal Chemistry, 129, 218–250. https://doi.org/10.1016/j.ejmech.2017.02.031
25. Patil, V., Tilekar, K., Mehendale-Munj, S., Mohan, R., & Ramaa, C. S. (2010). Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4- thiazolidinedione derivatives. European Journal of Medicinal Chemistry, 45(10), 4539–4544. https://doi.org/10.1016/j.ejmech.2010.07.014
26. Pérez, M. J., & Quintanilla, R. A. (2015). Therapeutic Actions of the Thiazolidinediones in Alzheimer’s Disease. PPAR Research, 2015. https://doi.org/10.1155/2015/957248
27. Prati, F., Cavalli, A., & Bolognesi, M. L. (2016). Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease. Molecules, 21(4). https://doi.org/10.3390/molecules21040466
28. Qiu, C., & Fratiglioni, L. (2018). Aging without Dementia is Achievable: Current Evidence from Epidemiological Research. Journal of Alzheimer’s Disease, 62(3), 933–942. https://doi.org/10.3233/JAD-171037
29. Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018). A perspective on multi-target drug discovery and design for complex diseases. Clinical and Translational Medicine, 7(1), 3. https://doi.org/10.1186/s40169-017-0181-2
30. Reddy, K. A., Lohray, B. B., Bhushan, V., Reddy, A. S., Kishore, P. H., Rao, V. V., … Rajagopalan, R. (1998). Novel euglycemic and hypolipidemic agent. Part 2: Antioxidant moiety as structural motif. Bioorganic and Medicinal Chemistry Letters, 8(9), 999–1002. https://doi.org/10.1016/S0960-894X(98)00159-0
31. Scott, L. J., & Goa, K. L. (2000). Galantamine: A review of its use in Alzheimer’s disease. Drugs, 60(5), 1095–1122. https://doi.org/10.2165/00003495-200060050-00008
32. Ulep, M. G., Saraon, S. K., & McLea, S. (2018). Alzheimer Disease. Journal for Nurse Practitioners, 14(3), 129–135. https://doi.org/10.1016/j.nurpra.2017.10.014
33. Yiannopoulou, K. G., & Papageorgiou, S. G. (2013). Current and future treatments for Alzheimer’s disease. Therapeutic Advances in Neurological Disorders, 6(1), 19–33. https://doi.org/10.1177/1756285612461679